Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 24;23(5):57.
doi: 10.1007/s11912-021-01038-6.

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Elisa Agostinetto  1   2 , Daniel Eiger  1 , Kevin Punie  3 , Evandro de Azambuja  4
Affiliations
Review

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Elisa Agostinetto et al. Curr Oncol Rep. .

Abstract

Purpose of review: Triple negative breast cancer (TNBC) accounts for approximately 10-15% of all breast cancers and it is associated with a poor prognosis. However, recent new effective treatment strategies have improved its outcomes. The aim of this review is to provide an overview on the emerging therapeutics for TNBC, describing both previously approved therapies that are currently being repurposed, as well as new target therapies that may improve patient outcomes.

Recent findings: Emerging therapies are forthcoming in TNBC's treatment landscape, including new post-neoadjuvant chemotherapy strategies, PARP inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates. Combination of different therapies such as AKT/PI3K/mTOR-inhibitors, other immunotherapeutic agents, CDK-inhibitors, antiandrogens, antiangiogenics, and histone deacetylase inhibitors is under clinical investigation. The treatment landscape for TNBC is gradually evolving towards a more personalized approach with promising expectations.

Trial registration: ClinicalTrials.gov NCT04408118.

Keywords: Breast cancer,; Immunotherapy; New therapies,; New treatments,; PARP inhibitors,; Triple-negative breast cancer,.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ CK. Cancer Statistics Review, 1975-2016 - SEER Statistics. based on November 2018 SEER data submission, posted to the SEER web site, April 2019.
    1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–34. https://doi.org/10.1158/1078-0432.CCR-06-3045 . - DOI - PubMed
    1. Caparica R, Lambertini M, de Azambuja E. How I treat metastatic triple-negative breast cancer. ESMO Open. 2019;4(Suppl 2):e000504. https://doi.org/10.1136/esmoopen-2019-000504 . - DOI - PubMed - PMC
    1. Reis-Filho JS, Tutt ANJ. Triple negative tumours: A critical review. Vol. 52, Histopathology. Histopathology. 2008:108–18. https://doi.org/10.1111/j.1365-2559.2007.02889.x .
    1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. Vol. 363, New England Journal of Medicine. Massachussetts Medical Society. 2010:1938–48. https://doi.org/10.1056/NEJMra1001389 .

MeSH terms

Substances

Associated data